Advocates question policy on EZ enrollment form | Burwell asks physicians to encourage insurance enrollment | Attorney: FDA wrong to change generic labeling rule
Web Version
October 24, 2014
PCMA SmartBrief
News for the PBM Industry

Legislative & Regulatory News
Advocates question policy on EZ enrollment form
Legal immigrants and naturalized citizens are barred from using the newly launched EZ application for health insurance on, and advocacy groups are worried that the policy will hinder efforts to enroll more Hispanic and Asian residents in insurance plans. The Detroit News/The Associated Press (10/23)
Share: LinkedInTwitterFacebookGoogle+Email
Burwell asks physicians to encourage insurance enrollment
HHS Secretary Sylvia Mathews Burwell has asked family physicians to encourage their patients to enroll in or stay enrolled in a health insurance plan. "As family physicians, you know how hard it is for your patients when they don't have insurance, or have coverage that's unaffordable or runs out just when they need it the most," Burwell said at an American Academy of Family Physicians meeting. The Hill (10/23)
Share: LinkedInTwitterFacebookGoogle+Email
Attorney: FDA wrong to change generic labeling rule
A proposed rule to allow generic drugmakers to independently update safety warnings is a bad idea because it would force makers of generic drugs to act like brand-name drugmakers and would lead to higher prices, Kirkland & Ellis attorney Jay Lefkowitz said in this interview. In addition, he said the draft goes against current law. The FDA "can't promulgate a regulation that is in conflict with the plain text of a statute," Lefkowitz said. The Wall Street Journal (tiered subscription model)/Pharmalot blog (10/23)
Share: LinkedInTwitterFacebookGoogle+Email
Drug Industry Spotlight
Mylan loses bid to market generic of Pfizer's cancer drug Sutent
A U.S. District Court ruled that Mylan infringed on Pfizer's patent on the cancer drug Sutent when it attempted to market a generic version. Pfizer owns the rights to the drug, which is approved for pancreatic and gastrointestinal tumors as well as advanced kidney cancer, until 2021. Reuters (10/23)
Share: LinkedInTwitterFacebookGoogle+Email
Opinion, Commentary & Analysis
Opinion: How high prices distort the search for new drugs
The pursuit of markets that support high prices is driving drugmakers to compete in narrow, already served niches that soak up investment that could go to developing drugs for patients with unmet needs, writes Dr. Peter Bach of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center. Forbes (10/23)
Share: LinkedInTwitterFacebookGoogle+Email
Happiness is like a butterfly: the more you chase it, the more it will elude you, but if you turn your attention to other things, it will come and sit softly on your shoulder."
-- Henry David Thoreau,
American writer and naturalist
Share: LinkedInTwitterFacebookGoogle+Email
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 216 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
(202) 207-3610
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Melissa Turner

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information